Skip to main content

23-06-2020 | Haematology | Video

EHA25 | Venetoclax addition improves survival in chemotherapy-ineliglible patients with AML

Courtney DiNardo discusses the phase 3 VIALE-A study supporting the addition of venetoclax to azacitidine as a new standard of care option for the first-line treatment of acute myeloid leukaemia patients who are ineligible for intensive chemotherapy (4:31).

Funding for independent interviews at EHA25 was provided by F. Hoffmann-La Roche Ltd, Basel, Switzerland.